Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The early signs of type 2 diabetes could be related to your gut. They may signal a warning risk long before you take a blood sugar test.

New research suggests that changes in the trillions of bacteria living in the gut may accurately predict future diabetes risk.

An analysis of microbiome data from more than 229,000 adults in the UK and US identified hundreds of bacterial changes linked with type 2 diabetes, including changes that appeared before measurable abnormalities in blood glucose.

The findings are being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan.

What Did Researchers Find?

Researchers from the University of Trento in Italy and collaborators in the UK analysed metagenomic data, which involves examining the DNA of microorganisms living in the gut.

The study included 229,025 people, of whom 3,627 had type 2 diabetes, 14,022 had prediabetes and 211,376 had normal blood glucose levels. The average age was 50, and about 74% of participants were women.

After accounting for factors including age, sex and body mass index, researchers identified 789 bacterial species associated with type 2 diabetes.

Of these, 168 were found at higher levels in people with diabetes, while 621 were present at lower levels.

One example was Enterocloster bolteae, which was more abundant in people with type 2 diabetes. In contrast, Romboutsia timonensis was found at lower levels.

Interestingly, 587 of the 789 bacterial species were also associated with unmedicated prediabetes, suggesting that some of these microbial changes may occur before diabetes is diagnosed.

Also read: Diabetes Linked To 55% Risk Of Kidney Disease, Heart Failure Or Death Within 10 Years: Study

Link Between Gut & Blood Sugar

The researchers looked at 135,093 people who had normal blood glucose and did not have diabetes or prediabetes. They also had information about how their blood sugar responded after eating.

Normally, blood glucose rises after a meal and then falls. If it remains elevated for longer than expected, it can indicate that the body's muscles are not responding properly to insulin, an early feature of insulin resistance.

Researchers found that people whose blood sugar remained elevated for longer were more likely to have the gut bacterial pattern linked with type 2 diabetes. The microbiome changes became more pronounced as insulin resistance increased.

Therefore, it was observed that the gut microbiome carried clues about metabolic problems even when standard blood glucose levels were still normal.

Also read: Muscle Loss In Middle Age May Signal Dementia Risk, Study Finds

Future Of Diabetes Testing

Currently, diabetes and prediabetes are diagnosed using tests like HbA1c, fasting blood glucose and oral glucose tolerance tests.

For people who have normal results, doctors generally assess future diabetes risk using factors like age, sex, body mass index and family history. A gut microbiome test is not currently part of routine diabetes screening.

The researchers believe microbiome analysis could eventually provide an additional layer of risk assessment, identifying people who could benefit from earlier lifestyle interventions.

Professor Tim Spector, one of the study's authors, Scientific Co-Founder, ZOE, said, “These latest findings represent a major step forward in understanding how our gut microbiome is linked directly with metabolic disease. Identifying these clear microbial changes before blood sugar levels worsen could lead to earlier intervention with food and lifestyle choices, as well as treatment options, to prevent T2D."

The researchers say that microbiome analysis should not replace existing tests for diabetes or prediabetes. The current findings show associations between particular bacterial patterns and diabetes risk.

The researchers also found that some of the bacteria making up the diabetes-related signature have never been isolated or cultivated in a laboratory and are new in terms of scientific investigation.

Additional research will be needed to assess whether these microbial changes can reliably predict who will develop diabetes and whether changing the microbiome can actually reduce that risk.

A Type 2 diabetes diagnosis increases the risk of developing chronic kidney disease (CKD) or heart failure (HF), or dying, by 55% within 10 years, according to analysis of data from more than 1.6 million patients across the US.

Within the first five years of a Type 2 diabetes diagnosis, the study found that the combined risk of developing CKD or heart failure, or dying, was 33% on average. By year 10, that combined risk rises to 55%.

Key Findings

The study shows within five years of a first diabetes diagnosis, the risk of developing CKD first was more than twice that of developing heart failure first (19.0% vs. 8.3%).

However, among people who developed heart failure first, there was a 42% risk of developing CKD within the following five years.

Conversely, among those who developed CKD first, there was a 23% risk of developing heart failure within the following five years.

"Our findings clearly show how the serious complications associated with type 2 diabetes rise sharply over time as the common combination of obesity, abnormal blood fats, high blood pressure and higher blood sugar damages blood vessels and vital organs," said Professor Naveed Sattar of the University of Glasgow in Scotland, UK.

Why The Findings Matter

Type 2 diabetes is projected to become the world's most prevalent epidemic disease, affecting an estimated 1.3 billion people by 2050.

It frequently occurs alongside obesity, high blood pressure, heart failure, CKD and depression, contributing substantially to the global burden of multi-morbidity.

The researchers say the findings highlight the importance of early, proactive and holistic management of Type 2 diabetes to help reduce the risk of serious complications.

"Our results emphasize the critical importance of detecting and treating type 2 diabetes thoroughly at the earliest opportunity to help reduce the risk of serious complications," Sattar added.

How Was The Study Conducted?

The team included 1,617,508 patients newly diagnosed with diabetes between January 1, 2010, and March 31, 2024, from across the US.

The average age of participants at enrollment was 59, and 51% were female. Among the 13% of patients who had a body mass index (BMI) recorded, the median was 30.9 kg/m².

Almost three-quarters (72%) of participants were living with dyslipidemia, or high levels of cholesterol and other fats in the blood, while more than two-thirds (68%) had high blood pressure.

How Are Diabetes, Kidney Disease And Heart Failure Linked?

The US Centers for Disease Control and Prevention (CDC) explains that diabetes, CKD and heart disease are interconnected.

High blood sugar can gradually damage the kidneys, reducing their ability to filter blood and potentially leading to CKD. When kidney function declines, it can also put additional stress on the heart.

Common Risk Factors

Risk factors that can overlap across diabetes, CKD and heart disease include:

• High blood sugar
• High blood pressure
• Family history
• Obesity
• Unhealthy diet
• Physical inactivity

Tips To Prevent

The CDC recommends lifestyle measures that can help reduce the risk of these conditions and their complications:

• Get active
• Choose healthy foods and drinks
• Quit smoking

A widely used supplement for joint health has been linked to a faster Alzheimer's progression, raising questions about whether glucosamine could turn mild cognitive impairment into dementia.

The study, published in Nature Metabolism, combined an analysis of health records of experiments involving human brain tissue and genetically modified mice. It showed that the supplement affected the brain in people already showing early signs of cognitive decline.

The findings, however, do not prove that glucosamine increases the progression of Alzheimer’s disease faster in humans.

What Is Glucosamine?

Glucosamine is a sugar-related compound widely sold as an over-the-counter supplement for joint discomfort and joint health. It is also found naturally in cartilage. It is used by older adults, the same age group in which cognitive impairment and dementia become more common.

Researchers at the University of Florida analysed health records collected between 2012 and 2024 to investigate whether glucosamine use was linked with Alzheimer's disease and related dementias.

"In the United States, there are about 7 million people living with Alzheimer's and millions more with related dementias such as Lewy body or frontotemporal dementia," said senior author Ramon Sun, Ph.D., Director of the Center for Advanced Spatial Biomolecule Research and associate director for innovation of UF's McKnight Brain Institute. "A lot of these people actively take an over-the-counter supplement that could be making their disease progression worse."

Also read: Muscle Loss In Middle Age May Signal Dementia Risk, Study Finds

What Were The Study's Findings?

About 8% of patients in both groups were using glucosamine supplement. This included 2,750 people with mild cognitive impairment and 1,896 people who already had Alzheimer's disease or a related dementia.

After accounting for age, sex and demographic factors, researchers found that people with mild cognitive impairment who used glucosamine had a 25% higher likelihood of progressing to dementia compared with those without documented use.

Among people who already had Alzheimer's disease or a related dementia, glucosamine use was also associated with a 25% higher risk of death during the study period. However, these were findings were based on collective health records, not a controlled clinical trial.

“The electronic health record data are very provocative,” said Matt Gentry, Ph.D., a study co-author. “While it's an association and not proof of causality, it does raise an important clinical question that now deserves much more attention.”

Also read: Rabies Day Exclusive: ‘We Need To Target The Source’ For A Rabies-Free India By 2030, Says Veterinary Epidemiologist

Glucosamine's Effects On Brain

The researchers identified a possible biological explanation involving a process called glycosylation. In simple terms, glycosylation involves attaching sugar structures to proteins. This is a normal process that helps proteins fold correctly, move around cells and perform their functions.

But the researchers found evidence that this process becomes excessively active in Alzheimer's disease. Their analysis suggested that glucosamine may intensify this abnormal “sugar-tagging” process in the brain.

The researchers tested the idea in genetically modified mice. Glucosamine increased the attachment of sugar molecules to proteins inside brain cells. The subjected mice's ability to recognise familiar animals also worsened.

When researchers used a chemical treatment to suppress the sugar-attachment process, the mice showed improved memory performance.

This does not prove the same mechanism occurs in humans, but it gave researchers a possible biological explanation for the association seen in the health records.

The researchers also examined brain tissue from people who had Alzheimer's disease. They found significantly more sugar attachment to proteins in Alzheimer's brain tissue compared to tissue from people without the disease. Taken together, the health-record analysis, mouse experiments and human brain-tissue findings point toward a connection between altered metabolism and Alzheimer's progression.

Despite the observation, a controlled clinical trial is needed to determine whether glucosamine itself accelerates Alzheimer's progression and whether certain patients are vulnerable.